QGEN Aug 2024 55.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
At close: 11:26AM EDT
Loading interactive chart…
- Zacks
Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now
QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.
- Zacks
QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification
QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.
- GlobeNewswire
QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater patient protection, transparency of information, and traceability of data // Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight InterpretVenlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE
© 2024 Yahoo. All rights reserved.